stop_circleTerminated/Withdrawn

Pharmacology, Clinical

Study on the safety of neladenoson bialanate, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as a single oral dose of 10 mg immediate release tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight

Trial purpose

Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure). Renal impairment which co-occurs in patients with heart failure is a common condition in which the kidneys are not filtering the blood as well as they should. The goal of the study is to learn more about the safety of neladenoson bialanate, how it is tolerated and the way the body absorbs, distributes and excretes the study dug given as a single oral dose of 10 mg immediate release tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight

Key Participants Requirements

Sex

All

Age

18 - 79 Years

Trial summary

Enrollment Goal
18
Trial Dates
November 2017 - December 2018
Phase
Phase 1
Could I Receive a placebo
No
Products
Neladenoson Bialanate (BAY1067197)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
CRS Clinical-Research-Services Kiel GmbHKiel, 24105, Germany
Completed
APEX GmbHMünchen, 81241, Germany
Withdrawn
SocraTec R&D Clinical WardErfurt, 99084, Germany

Primary Outcome

  • Cmax for BAY 84-3174
    Maximum observed drug concentration in measured matrix after single dose administration
    date_rangeTime Frame:
    Pre-dose up to approximately 6 weeks after dosing
  • AUC for BAY 84-3174
    Area under the concentration vs. time curve from zero to infinity after single dose administration
    date_rangeTime Frame:
    Pre-dose up to approximately 6 weeks after dosing
  • Cmax,norm for BAY 84-3174
    Cmax divided by dose per body weight after single dose administration
    date_rangeTime Frame:
    Pre-dose up to approximately 6 weeks after dosing
  • AUCnorm for BAY 84-3174
    AUC divided by dose per body weight after single dose administration
    date_rangeTime Frame:
    Pre-dose up to approximately 6 weeks after dosing
  • Cmax,u for BAY 84-3174
    Cmax of unbound drug after single dose administration
    date_rangeTime Frame:
    Pre-dose up to approximately 6 weeks after dosing
  • AUCu for BAY 84-3174
    AUC of unbound drug after single dose administration
    date_rangeTime Frame:
    Pre-dose up to approximately 6 weeks after dosing
  • fu for BAY 84-3174
    Fraction of free (unbound) drug in plasma or serum after single dose administration
    date_rangeTime Frame:
    At 4 hours after dosing

Secondary Outcome

  • Number of subjects with treatment-emergent adverse events (TEAEs)
    date_rangeTime Frame:
    Up to approximately 6 weeks after dosing

Trial design

Investigation of pharmacokinetics, safety and tolerability of neladenoson bialanate in male and female subjects with renal impairment and in age-, gender-, and weight-matched healthy subjects following a single oral dose of 10 mg neladenoson bialanate given as IR tablet in a single-center, nonrandomized, non-controlled, non-blinded, study with group stratification
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Basic Science
Allocation
Non-randomized
Blinding
N/A
Assignment
Parallel Assignment
Trial Arms
4